Extra-organ metastatic retroperitoneal tumor of the right iliac region in a 26-year-old female patient. Problem: unclassifiable tumor

The basis of current oncology is the verification of the disease. Only after the pathomorphological establishment of a clinical diagnosis, the treatment tactics of a particular patient are collectively selected. Now, in most cases, only pathomorphological diagnostics is not enough, it is necessary to conduct immunohistochemical and even molecular genetic researches, some of which are possible only in large federal referral centers. However, despite the existence of wide possibilities and detailed pathohistological classifications of neoplasms, with the development of modern diagnostic technologies, the medical community began to understand that some pathological processes go beyond the developed methods of diagnosis and cannot be verified within existing classifications. This way, patients with unclassifiable tumors currently do not have the opportunity to receive antitumor treatment based on evidence-based medicine, due to the lack of large-scale researches and clinical recommendations for the treatment of these types of tumors. The main purpose of the article is to once again draw the attention of the oncological community to the existence of unclassifiable tumors, in order to continue collecting information and jointly develop tactics for the diagnosis and treatment of these rare tumors.

1. Neishtadt E.L., Ozhiganova I.N. Ovarian tumors: a practical guide. St. Petersburg: FOLIANT Publishing House LLC, 2017. 352 p. (In Russ.)

2. Danilova N.V., Oleynikova N.A., Malkov P.G. 2019 WHO classification of gastric epithelial tumors, 5th ed. Russian Journal of Archive of Patology, 2020, Vol. 82, No. 4, pp. 58– 69 (In Russ.)

3. Toneev E.A., Martynov A.A., Lazarevskiy M.M., Pikin O.V. Rare case of primary hepatoid adenocarcinoma of the lung. Siberian Journal of Oncology, 2022, Vol. 21, No 2, pp. 150–155 (In Russ.)

4. Paklina O.V., Setdikova G.R., Gordienko E.N., Nikitin P.N. Hepatoid adenocarcinoma of the lung with multiple metastases to the small intestine. Pathology Archive, 2011, Vol. 73, No. 2, pp. 40–42 (In Russ.)

5. Miyama Y., Fujii T., Murase K., Takaya H., Kondo F. Hepatoid adenocarcinoma of the lung mimicking metastatic hepatocellular carcinoma // Autops Case Rep. 2020. Vol. 10, No. 2. e2020162. doi.org/10.4322/acr.2020.162.

6. Nargund A., Agrawal M., Dharmalingam P., Amirtham U., Pai M. Primary hepatoid adenocarcinoma of the lung: A study of two cases with review of literature // Indian J. Med. Paediatr. Oncol. 2020. Vol. 41, No. 4. Р. 591–595. doi: 10.4103/ijmpo.ijmpo_245_19.

7. Pasricha S., Grover S., Kamboj M., Bansal D., Batra U., Gupta G., Sharma A., Durga G., Jajodia A., Koyyala V.P., Mehta A. Hepatoid adenocarcinoma of lung: A diagnostic challenge — Series of six cases with histopathological, predictive molecular and PD.L1 assessment // Indian J. Pathol. Microbiol. 2021. Vol. 64, No. 1. Р. 128–131. doi: 10.4103/IJPM.IJPM_334_20.

8. Haninger D.M., Kloecker G.H., Bousamra Ii.M., Nowacki M.R., Slone S.P. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature // Mod. Pathol. 2014. Vol. 27, No. 4. Р. 535–542. doi: 10.1038/modpathol.2013.170.

9. Ishikura H., Kanda M., Ito M., Nosaka K., Mizuno K. Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoproteinproducing lung carcinoma // Virchows Arch. A Pathol. Anat. Histopathol. 1990. Vol. 417, No. 1. Р. 73–80. doi: 10.1007/BF01600112.

10. Supriatna Y., Kishimoto T., Uno T., Nagai Y. et al. Evidence for hepatocellular differentiation in alpha-fetoproteinnegative gastric adenocarcinoma with hepatoid morphology: study with in situ hybridisation for albumin mRNA, Hiroshi Ishikura Affiliations expand // Pathology. 2005. Jun; Vol. 37, No. 3. Р. 211–215. doi: 10.1080/00313020500099221. PMID: 16175893. doi: 10.1080/00313020500099221.

11. Aizawa K., Motoyama T., Suzuki S. et al. Different characteristics of hepatoid and non-hepatoid alpha-fetoproteinproducing gastric carcinomas: an experimental study using xenografted tumors // Int. J. Cancer. 1994. Aug 1; Vol. 58, No. 3. Р. 430–435. doi: 10.1002/ijc.2910580321. PMID:7519587.

12. Nasu M., Soma T., Fukushima H., Kudo K., Matsubara O. Hepatoid carcinoma of the lung with production of alphafetoprotein and abnormal prothrombin: an autopsy case report // Mod. Pathol. 1997. Vol. 10, No. 10. Р. 1054–1058.

13. Su J.S., Chen Y.T., Wang R.C., Wu C.Y., Lee S.W., Lee T.Y. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review // World J. Gastroenterol. 2013. Jan 21; Vol. 19, No. 3. Р. 321– 327. doi: 10.3748/wjg.v19.i3.321. PMID: 23372352; PMCID: PMC3554814.

14. Clinical recommendations of the Ministry of the Russian Federation. 2024 (In Russ.)

15. Practical recommendations for the treatment of malignant tumors of the Russian Society of Clinical Oncology RUSSCO. 2023 (In Russ.)

16. Интернет-ресурс https://dpathology.ru/ Дата обращения 31.07.2024.

17. Nagtegaal I.D., Odze R.D., Klimstra D., Paradis V., Rugge M., Schirmacher P., Washington K.M., Carneiro F., Cree I.A; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system // Histopathology. 2020 Jan; Vol. 76, No. 2. Р. 182–188. doi: 10.1111/his.13975. Epub 2019. Nov 13. PMID: 31433515; PMCID: PMC7003895.

18. Meihui L., Ying F., Hongyang L. Hepatoid Adenocarcinoma of the Lung // Technol. Cancer Res. Treat. 2021. JanDec. Vol. 20. Р. 15330338211057983. doi: 10.1177/15330338211057983.